Cargando…
When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective
Resistance to drug treatment is a critical barrier in cancer therapy. There is an unmet need to explore cancer hallmarks that can be targeted to overcome this resistance for therapeutic gain. Over time, metabolic reprogramming has been recognised as one hallmark that can be used to prevent therapeut...
Autores principales: | Zhang, Zhiqiang, Bao, Chaohui, Jiang, Lu, Wang, Shan, Wang, Kankan, Lu, Chang, Fang, Hai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854130/ https://www.ncbi.nlm.nih.gov/pubmed/36686803 http://dx.doi.org/10.3389/fonc.2022.1054233 |
Ejemplares similares
-
Spatial metabolomics in head and neck tumors: a review
por: Zheng, Ye, et al.
Publicado: (2023) -
Bulk and Spatially Resolved Extracellular Metabolome of Free-Living Nitrogen Fixation
por: Smercina, Darian N., et al.
Publicado: (2022) -
Comparing DESI-MSI and MALDI-MSI Mediated Spatial Metabolomics and Their Applications in Cancer Studies
por: He, Michelle Junyi, et al.
Publicado: (2022) -
Progress in the Treatment of HIV-Associated Lymphoma When Combined With the Antiretroviral Therapies
por: Wang, Chaoyu, et al.
Publicado: (2022) -
Metabolic bulk volume from FDG PET as an independent predictor of progression-free survival in follicular lymphoma
por: So, Heejune, et al.
Publicado: (2023)